After clearing Novo Nordisk’s semaglutide treatments Ozempic and Wegovy to reduce the risk of major adverse cardiovascular ...

Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart.

In a significant stride for chronic disease management, FDA granted approvals for Roche’s lupus nephritis treatment and Novo Nordisk’s cardiovascular-risk-reducing oral semaglutide for adults with ...

Novo Nordisk announced that the European Medicines Agency (EMA) has approved an update to the label for Rybelsus (oral semaglutide).

Medically reviewed by Lindsay Cook, PharmD Key Takeaways Ozempic may help protect kidney function in people with type 2 ...

Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's ...

Novo Nordisk acquires Akero Therapeutics for $5.2B to boost its metabolic disease pipeline with EFX. Check out what this ...

Danish drugmaker Novo Nordisk (NVO) on Tuesday said that its blockbuster drug Ozempic is now approved in Canada to reduce the risk of kidney function decline, end-stage kidney disease, and ...

NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.

The algorithm will be added to Roche's navify library of clinical decision-making algorithms and other digital health technologies (DHTs), designed to assist healthcare systems in delivering faster ...

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...